How Pharmaceutical Companies Are Using AI in Clinical Development
Every major pharmaceutical company has announced an AI strategy. What they are actually doing, versus what they are announcing, is a more interesting question.
Spend time reading pharmaceutical industry press releases and you will encounter a consistent picture: AI is transforming drug development, compressed timelines, smarter trial designs, predictive safety signals, automated regulatory submissions. The announcements are frequent and ambitious.
Spend time talking to people inside these organisations, which we have done extensively while developing NousLab's capabilities for pharmaceutical research teams, and you get a more nuanced picture. AI is being used productively in specific, well-defined parts of the clinical development process. It is being oversold in others. And there is a substantial gap, in most organisations, between what is being announced and what is reliably deployed at scale.
This is not a criticism. It is the normal pattern of technology adoption in a heavily regulated, risk-averse industry. The gap between announcement and deployment is smaller than it was three years ago, and it is narrowing. Understanding where the value is genuinely materialising helps research and development teams make better decisions about where to invest their own attention and resources.
Clinical trial design and protocol optimisation
This is one of the areas where AI tools are being deployed most actively and where the evidence of impact is most concrete. Protocol design is a domain with a large historical database of trial outcomes, which makes it amenable to machine learning approaches. Patterns that predict protocol amendments, early stopping, enrolment challenges, and safety events have been identified in these datasets, and tools that surface these patterns during the design phase have demonstrated utility in reducing costly mid-trial adjustments.
Pfizer, Novartis, AstraZeneca, and several large CROs have published, or publicly discussed, applications of AI to protocol review and optimisation. The specific claims vary, but the consistent finding is that models trained on historical protocol data can identify design features associated with recruitment challenges and protocol amendments with better than chance accuracy. Even modest improvements in protocol robustness, at the scale of a large pharmaceutical company's trial portfolio, translate into material reductions in development cost and time.
The limitation is that these tools work best for trial types and indications that are well-represented in the training data. Novel mechanisms, first-in-class indications, and patient populations without historical comparators challenge these approaches. The AI optimises within the space of what has been done before. When the design problem requires genuine innovation, human methodological expertise remains the primary input.
Patient recruitment and site selection
Patient recruitment is consistently cited as the primary cause of clinical trial delays, and it is an area where AI-assisted tools have been adopted relatively broadly. Electronic health record screening to identify potentially eligible patients at participating sites, predictive models for site performance based on historical data, and adaptive randomisation tools that respond to real-time enrolment patterns are all in active use at major sponsors and CROs.
The published evidence is promising. A 2022 analysis published in Clinical Trials found that AI-assisted patient identification using EHR data at academic medical centres reduced screening failure rates by 30 to 40 percent compared to conventional site-based identification for complex inclusion criteria. Similar analyses have been reported for oncology trials, where matching patients to trials with genomic eligibility criteria is particularly well-suited to automated approaches.
The implementation challenges are real and often underreported. EHR data quality varies substantially across sites and geographies. Patients identified as potentially eligible through data screening still require clinical review and informed consent processes that are not amenable to automation. Privacy regulations in different jurisdictions create variable constraints on what data can be accessed and how. The AI tool is useful. The deployment is a data integration and change management challenge as much as a technical one.
Pharmacovigilance and safety signal detection
Post-marketing pharmacovigilance, monitoring adverse event reports for signals of unexpected safety problems, is a domain where AI adoption is well-advanced and where the regulatory environment has been relatively supportive. The FDA's Sentinel system, which uses electronic health data from over 300 million patients to monitor drug safety signals, has incorporated machine learning components for signal detection since the mid-2010s. The EMA's EudraVigilance database and Japan's PMDA adverse drug reaction database are pursuing similar AI-assisted signal detection frameworks.
At the company level, tools for processing and classifying individual case safety reports have reduced the manual burden of pharmacovigilance operations substantially. More sophisticated systems attempt to detect safety signals in real-world data that would not emerge from individual case reports, identifying patterns of co-occurrence between drug use and adverse events that are too infrequent or too delayed to be visible in trial data.
The methodological challenge in AI-assisted pharmacovigilance is distinguishing true drug-event associations from confounding by indication, concurrent medication use, and the underlying disease epidemiology. This is the same confounding problem that challenges all observational research, and it does not become simpler when the analysis is automated. FDA's real-world evidence programme is developing frameworks for evaluating these analyses, but the methodological standards are still evolving.
Regulatory submissions and document intelligence
Pharmaceutical regulatory submissions are among the most document-heavy processes in any industry. A new drug application may contain hundreds of thousands of pages across dozens of modules, including preclinical study reports, clinical study reports, pharmacology data, manufacturing quality documentation, and risk management plans. The work of compiling, cross-referencing, and quality-checking these documents is substantial, expensive, and error-prone.
AI tools for document intelligence, entity extraction, cross-reference validation, and consistency checking across submission modules have been adopted by regulatory affairs teams at several large pharmaceutical companies. The productivity gains in regulatory operations are real and measurable, and this is an area where the value proposition is relatively straightforward: reducing the human hours required for document-intensive work without requiring clinical expertise in the AI system itself.
More ambitious applications, AI-assisted generation of regulatory narratives or clinical study report sections, are in development but have been adopted more cautiously. The regulatory consequences of errors in submission documents are severe, which creates a higher threshold for confidence before autonomous AI generation is accepted in operational workflows. The EMA's AI strategy, the FDA's AI/ML action plan, and China's NMPA guidelines on AI in medical products are all developing frameworks for how AI-generated content will be treated in regulatory submissions, but none have yet reached final guidance that addresses autonomous narrative generation directly.
The honest assessment of where we are
AI is adding genuine, measurable value in pharmaceutical clinical development in specific domains. Protocol optimisation, patient identification, pharmacovigilance signal detection, and regulatory document processing are all areas where the technology has been deployed, validated, and is generating returns that justify the investment.
It has not yet demonstrably improved clinical success rates, the attrition from Phase I to approval that has remained stubbornly around 10 to 15 percent for decades. Improving success rates requires getting the science right, understanding which targets matter, which patient populations respond, and which safety risks are acceptable. These are questions where AI provides better tools for processing existing knowledge, not yet tools for generating the novel insights that determine whether a molecule works.
Research teams working within pharmaceutical organisations or supporting them who want a more complete and critically assessed picture of where AI tools have demonstrated utility versus where they remain aspirational will find the literature is thinner and more methodologically heterogeneous than the press coverage would suggest. Working through that literature carefully, distinguishing between vendor-sponsored publications and independent evaluations, is exactly the kind of evidence work where systematic AI-assisted synthesis adds genuine value. Our pharmaceutical research use cases are a good starting point if you are approaching this question.
